312 results
Name Type Target Compound Name Phase
Collaboration: Diffusion Pharmaceuticals / University of Virginia

Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19

New Therapies (Small Molecule) Not determined Trans sodium crocetinate (TSC) In Clinic

Novan intends to screen NVN1000 against a number of viruses, including SARS-CoV-2

New Therapies (Small Molecule) Not determined Berdazimer sodium (NVN1000) Pre-Clinical
Flow Pharma

Vaccine (Peptide) Nucleocapsid Protein FlowVax™ Pre-Clinical
Tongji Hospital

A Pilot Study of Sildenafi in the Treatment of COVID-19

New Therapies (Small Molecule) PDE 5 Sildenafil Phase III
HonorHealth Research Institute

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

New Therapies (Small Molecule) Plasmodium cytochrome bc1 Atovaquone In Clinic
Collaboration: Jagiellonian University (Malopolska Centre of Biotechnology); Nanjing University

HTCC compound (N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride), which may be used as potential inhibitor of currently circulating highly pathogenic coronaviruses –SARS-CoV-2 and MERS-CoV.

New Therapies (Small Molecule) Potential Inhibitor of SARS-CoV-2 HTCC compound (N-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride Pre-Clinical

Clinical trials of multiple myeloma drug plitidepsin

Research (Drug Repurposing) Protein eEF1A Aplidin (plitidepsin) Phase II
Imperial College London

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomized Controlled Trial.

New Therapies (Small Molecule) Purinergic receptor P2Y G protein-coupled 12 Clopidogrel In Clinic
Materno-Perinatal Hospital of the State of Mexico

Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

New Therapies (Small Molecule) Pyruvate ferredoxin oxidoreductase Nitazoxanide Phase IV
Collaboration: University of California, Irvine UCI Medical Center and UC San Diego Medical Center

Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection.

Research (Drug Repurposing) RNA-dependent RNA pol Remdesivir (GS-5734) Completed
Bausch Health

Clinical trial program evaluating an investigational use of VIRAZOLE® (Ribavirin for Inhalation Solution, USP) in combination with standard of care therapy to treat hospitalized adult patients with respiratory distress due to COVID-19. Because ribavirin is a synthetic nucleoside that works to stop viral replication, VIRAZOLE may be effective in reducing the severity of COVID-19 infection

New Therapies (Small Molecule) RNA-dependent RNA polymerase Virazole ribavirin for inhalation In Clinic

Will begin screening its library of novel reactive aldehyde species (RASP) inhibitors, including ADX-629 and reproxalap, for potential anti-inflammatory and antiviral activity in the treatment of COVID-19 infection

New Therapies (Small Molecule) Reactive aldehyde species Reproxalap Pre-Clinical
University of California, San Franscico

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

New Therapies (Small Molecule) Ribosomal 50S subunit Chloramphenicol Pre-Clinical
University of California, San Franscico

A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

New Therapies (Small Molecule) Ribosomal 50S subunit Linezolid Pre-Clinical

New Therapies (Small Molecule) S1PR1; S1P1; EDG1 Gilenya fingolimod Phase II
Collaboration: National University of Health (NIH); and University of Pennsylvania

The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission

Research (Modeling) SARS-CoV-2 N/A Research
Penn State University

We show how influenza like illness (ILI) outpatient surveillance data can be used to estimate the prevalence of SARS-CoV-2.

SARS-CoV-2 Unnamed Research
London School of Hygiene and Tropical Medicine

We created OpenSAFELY: a secure health analytics platform covering 40% of all patients in England, holding patient data within the existing data centre of a major primary care electronic health records vendor. Primary care records of 17,278,392 adults were pseudonymously linked to 10,926 COVID-19-related deaths. COVID-19-related death was associated with: being male (hazard ratio (HR) 1.59, 95% confidence interval (CI) 1.53–1.65); older age and deprivation (both with a strong gradient); diabetes; severe asthma; and various other medical conditions. Compared with people with white ethnicity, Black and South Asian people were at higher risk even after adjustment for other factors (HR 1.48, 1.30–1.69 and 1.44, 1.32–1.58, respectively). We have quantified a range of clinical risk factors for COVID-19-related death in the largest cohort study conducted by any country to date. OpenSAFELY is rapidly adding further patients’ records; we will update and extend results regularly.

Research (Modeling) SARS-CoV-2 N/A Research
Collaboration: Aptorum; Covar

Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and Acticule Infectious Disease Platform

New Therapies (Small Molecule) SARS-CoV-2 3CL-Protease; Viral RNA-dep. RNA pol SACT-COV19 (3 repurposed drugs) Pre-Clinical
Scripps Research

Molecular understanding of neutralizing antibody responses to SARS-CoV-2 could accelerate vaccine design and drug discovery. We analyzed 294 anti-SARS-CoV-2 antibodies and found that IGHV3-53 is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein. Co-crystal structures of two IGHV3-53 neutralizing antibodies with RBD, with or without Fab CR3022, at 2.33 to 3.20 Å resolution revealed that the germline-encoded residues dominate recognition of the ACE2 binding site. This binding mode limits the IGHV3-53 antibodies to short CDR H3 loops, but accommodates light-chain diversity. These IGHV3-53 antibodies show minimal affinity maturation and high potency, which is promising for vaccine design. Knowledge of these structural motifs and binding mode should facilitate design of antigens that elicit this type of neutralizing response.

Research (Antibody Response) SARS-CoV-2 Spike Protein N/A Research
Collaboration: Institute for Basic Science (IBS); Seoul National University; Korea Centers for Disease Control and Prevention

The SARS-CoV-2 transcriptome andepitranscriptome reveal a complex arrayof canonical and non-canonical viraltranscripts with RNA modifications.

Research (Modeling) SARS-CoV-2 Transcriptome N/A Research
Collaboration: Northern Arizona University (NAU) & Translational Genomic Research Institute (TGen)

Sequencing the SARS-CoV-2 genome

Research (Epidemiology) SARS-CoV-2 genetic material N/A Pre-Clinical
Queensland Alliance for Environmental Health Sciences in Australia

Using wastewater analysis to determine the scale of SARS-CoV-2 outbreak

Research (Epidemiology) SARS-CoV-2 genetic material N/A Pre-Clinical
KWR Watercycle Research Institute

Using wastewater analysis to try and determine the scale of SARS-CoV-2 outbreak in the Netherlands

Research (Epidemiology) SARS-CoV-2 genetic material N/A Pre-Clinical
University of Arizona, Water and Energy Sustainable Technology Center

Conducting "sewage surveillance" of communities to determine the presence of the virus in positive and asymptomatic cases

Research (Epidemiology) SARS-CoV-2 genetic material N/A Pre-Clinical